A
- Agonist
- An agonist is a substance that binds to a receptor and switches it on, copying the effect of the body's own signalling molecule.
B
- Biomarker
- A biomarker is a measurable sign, such as a blood test result, used as a stand-in for something researchers want to assess; a change in a biomarker is not the same as a person's health improving.
D
- Double-Blind, Placebo-Controlled Trial
- In a double-blind, placebo-controlled trial, neither the participants nor the researchers know who received the active treatment or an inactive placebo until the study ends.
G
- Growth Hormone Secretagogue
- A growth hormone secretagogue is a substance that prompts the pituitary gland to release growth hormone.
H
- Half-Life
- A half-life is the time it takes for the amount of a substance in the body to fall by half.
I
M
- Marketing Authorisation
- A marketing authorisation is the formal approval a regulator such as the MHRA gives before a medicine can lawfully be sold or supplied for a stated medical use.
- Meta-Analysis
- A meta-analysis combines the numerical results of several studies on the same question to give one more precise estimate.
- MHRA (Medicines and Healthcare products Regulatory Agency)
- The MHRA, the Medicines and Healthcare products Regulatory Agency, is the UK regulator that authorises medicines and monitors their safety.
N
- NICE Technology Appraisal
- A NICE technology appraisal is guidance from the National Institute for Health and Care Excellence on whether a treatment is recommended for use in the NHS.
O
- Observational Study (Case Series and Case Reports)
- An observational study, case series or case report describes what happened to people without assigning treatments, so it can show a link but cannot prove cause.
- Off-Label Use
- Off-label use means using a licensed medicine for a purpose or in a way that its licence does not cover.
- Orphan Drug Designation
- Orphan drug designation is a regulatory status that encourages development of treatments for rare conditions; it is not approval to market a medicine.
P
- Peer-Reviewed
- Peer-reviewed means independent experts in the field checked a study before a journal published it.
- Phase 1, 2 and 3 Clinical Trials
- Phase 1, 2 and 3 clinical trials are successive stages of testing in people, moving from early safety checks to larger studies of whether a treatment works.
- Preclinical / Animal Model Research
- Preclinical research is done in animals, usually mice or rats, before or instead of human trials, and its results do not always carry over to people.
- Prescription-Only Medicine (POM)
- A prescription-only medicine, or POM, is a UK medicine that can lawfully be supplied only with a prescription from a qualified prescriber.
- Primary Source and Secondary Source
- A primary source is the original report of a study's own data, while a secondary source, such as a review, describes research done by others.
R
- Randomised Controlled Trial (RCT)
- A randomised controlled trial, or RCT, assigns participants to treatments by chance and compares the groups to test whether a treatment has an effect.
- Receptor
- A receptor is a protein on or inside a cell that a specific molecule binds to, triggering a response in that cell.
S
- Statistical Significance and Confidence Interval
- Statistical significance and the confidence interval describe how likely a result is to be due to chance and the range within which the true effect probably lies.
- Systematic Review
- A systematic review finds and appraises all the studies on a question using a set, documented method, to summarise what the evidence shows.
U
- Unlicensed Medicine
- An unlicensed medicine is a medicinal product that holds no UK marketing authorisation.
Y
- Yellow Card Scheme
- The Yellow Card Scheme is the UK system for reporting suspected side effects of medicines; a report does not prove the medicine caused the problem.
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.